Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen All but Throws in the Towel on Once-Promising Alzheimer's Drug
03:50pm, Thursday, 12'th May 2022
Once heralded as the “golden child,” the Alzheimer's drug Aduhelm has all but been abandoned by its parent Biogen Inc. ( BIIB , Financial), leaving the Cambridge, Massachusetts-based biotech scram
3 Healthcare Stocks That Are Too Cheap to Ignore
10:00am, Wednesday, 11'th May 2022 The Motley Fool
A rebound could be on the horizon.
3 Healthcare Stocks That Are Too Cheap to Ignore
06:00am, Wednesday, 11'th May 2022
A rebound could be on the horizon.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
06:05pm, Tuesday, 10'th May 2022 Zacks Investment Research
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
03:48pm, Tuesday, 10'th May 2022
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Best Stocks To Buy Now? 5 Health Care Stocks In Focus
02:30pm, Monday, 09'th May 2022
Could these health care stocks be the remedy to investors' recent stock market pains?
Is This Growth Stock Defeated After Collapsing 22% in a Year?
02:30pm, Saturday, 07'th May 2022 The Motley Fool
Things haven't been this bad for the company in quite a long time.
Is This Growth Stock Defeated After Collapsing 22% in a Year?
10:30am, Saturday, 07'th May 2022
Things haven't been this bad for the company in quite a long time.
Drug companies are making an accounting change after the SEC cracked down on Biogen
05:07pm, Friday, 06'th May 2022 MarketWatch
Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in w
The Zacks Analyst Blog Highlights Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group
10:07am, Friday, 06'th May 2022 Zacks Investment Research
Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group have been included in this Analyst Blog.
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
03:45pm, Thursday, 05'th May 2022 Zacks Investment Research
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Analyst Upgrades and Research Reports for Oracle, Union Pacific, Ford & Others
03:32pm, Thursday, 05'th May 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Union Pacific Corporation (UNP), and Ford Motor Company (F).
Beset by challenges with its Alzheimer's drug, Biogen pivots
11:38am, Thursday, 05'th May 2022 MarketWatch
The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug.
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
11:30am, Thursday, 05'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass. and PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investi
